Stemline Therapeutics (STML) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Stemline Therapeutics (STML) Misses Q4 EPS by 1c

Stemline Therapeutics Reports Fourth Quarter 2015 Financial Results

March 14, 2016 7:32 AM EDT

NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML) today reported financial results for the quarter ended December 31, 2015.

Ivan Bergstein, M.D., Stemlines Chief Executive Officer, commented, During the fourth quarter, we made significant progress across all three of our development programs. Key achievements included 1) generating and presenting data from our ongoing Phase 2 trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) which we have designed to support potential registration, 2) treating our first patient in the second stage of our Phase 2 program of SL-701 in advanced brain... More